View Article PDF

Efficacy and safety of betahistine treatment in patients with Meniere s diseasePatients suffering from Meniere s disease may be subject to severe vertigo. Betahistine is often prescribed in such patients to prevent the vertigo. However, there is doubt that this treatment is efficacious.This randomised, double-blind trial compared the use of betahistine in either low or high dosage with a placebo. Seventy-three patients were treated with betahistine 24mg twice daily, 74 with 48mg three times per day, and 74 with placebo.The primary outcome sought was the number of attacks of vertigo per 30 days during assessment period at months 7 to 9. Incidence of attacks did not differ between the 3 groups. The treatments were well tolerated, with no safety issues. BMJ 2016;352:h6816 Medication adherence 1 month after hospital dischargeAdherence to prescription medications as reported in the literature is suboptimal, with studies reporting non-adherence rates between 20 and 50 %. This paper reports on a study evaluating this issue in Australia.The researchers conducted a prospective cohort study of 68 patients, comparing admission and discharge medication regimens to self-reported regimens 30-40 days after discharge from hospital. They found that 27 of the 68 patients (39.7%) were non-adherent to one or more of their regular medications at follow-up. Intentional and unintentional non-adherence contributed equally.It was noted that the presence of a carer responsible for medications was associated with a significantly lower non-adherence rate. They suggest that the prescribing physicians need to establish a better therapeutic relationship with their patients as this may reduce intentional non-adherence. Internal Medical Journal 2016;46,185-192 Metformin versus placebo in obese pregnant women without diabetes mellitusObesity is associated with an increased risk of adverse pregnancy outcomes. Metformin improves insulin sensitivity and in pregnant patients with gestational diabetes it leads to less weight gain than occurs in those who do not take metformin.This trial aimed to assess whether metformin administered to obese pregnant women from 12-18 weeks of gestation would reduce the median neonatal birth weight as well as the incidences of adverse neonatal outcomes. There were 202 women in the metformin group and 198 in the placebo group.There was no significant difference in the median neonatal birth weights between the metformin and placebo groups. There were also no differences between the groups in the incidence of gestational diabetes, large-for-gestational-age neonates, or adverse neonatal outcomes. N Eng J Med 2016;374:434-43

Summary

Abstract

Aim

Method

Results

Conclusion

Author Information

Acknowledgements

Correspondence

Correspondence Email

Competing Interests

For the PDF of this article,
contact nzmj@nzma.org.nz

View Article PDF

Efficacy and safety of betahistine treatment in patients with Meniere s diseasePatients suffering from Meniere s disease may be subject to severe vertigo. Betahistine is often prescribed in such patients to prevent the vertigo. However, there is doubt that this treatment is efficacious.This randomised, double-blind trial compared the use of betahistine in either low or high dosage with a placebo. Seventy-three patients were treated with betahistine 24mg twice daily, 74 with 48mg three times per day, and 74 with placebo.The primary outcome sought was the number of attacks of vertigo per 30 days during assessment period at months 7 to 9. Incidence of attacks did not differ between the 3 groups. The treatments were well tolerated, with no safety issues. BMJ 2016;352:h6816 Medication adherence 1 month after hospital dischargeAdherence to prescription medications as reported in the literature is suboptimal, with studies reporting non-adherence rates between 20 and 50 %. This paper reports on a study evaluating this issue in Australia.The researchers conducted a prospective cohort study of 68 patients, comparing admission and discharge medication regimens to self-reported regimens 30-40 days after discharge from hospital. They found that 27 of the 68 patients (39.7%) were non-adherent to one or more of their regular medications at follow-up. Intentional and unintentional non-adherence contributed equally.It was noted that the presence of a carer responsible for medications was associated with a significantly lower non-adherence rate. They suggest that the prescribing physicians need to establish a better therapeutic relationship with their patients as this may reduce intentional non-adherence. Internal Medical Journal 2016;46,185-192 Metformin versus placebo in obese pregnant women without diabetes mellitusObesity is associated with an increased risk of adverse pregnancy outcomes. Metformin improves insulin sensitivity and in pregnant patients with gestational diabetes it leads to less weight gain than occurs in those who do not take metformin.This trial aimed to assess whether metformin administered to obese pregnant women from 12-18 weeks of gestation would reduce the median neonatal birth weight as well as the incidences of adverse neonatal outcomes. There were 202 women in the metformin group and 198 in the placebo group.There was no significant difference in the median neonatal birth weights between the metformin and placebo groups. There were also no differences between the groups in the incidence of gestational diabetes, large-for-gestational-age neonates, or adverse neonatal outcomes. N Eng J Med 2016;374:434-43

Summary

Abstract

Aim

Method

Results

Conclusion

Author Information

Acknowledgements

Correspondence

Correspondence Email

Competing Interests

For the PDF of this article,
contact nzmj@nzma.org.nz

View Article PDF

Efficacy and safety of betahistine treatment in patients with Meniere s diseasePatients suffering from Meniere s disease may be subject to severe vertigo. Betahistine is often prescribed in such patients to prevent the vertigo. However, there is doubt that this treatment is efficacious.This randomised, double-blind trial compared the use of betahistine in either low or high dosage with a placebo. Seventy-three patients were treated with betahistine 24mg twice daily, 74 with 48mg three times per day, and 74 with placebo.The primary outcome sought was the number of attacks of vertigo per 30 days during assessment period at months 7 to 9. Incidence of attacks did not differ between the 3 groups. The treatments were well tolerated, with no safety issues. BMJ 2016;352:h6816 Medication adherence 1 month after hospital dischargeAdherence to prescription medications as reported in the literature is suboptimal, with studies reporting non-adherence rates between 20 and 50 %. This paper reports on a study evaluating this issue in Australia.The researchers conducted a prospective cohort study of 68 patients, comparing admission and discharge medication regimens to self-reported regimens 30-40 days after discharge from hospital. They found that 27 of the 68 patients (39.7%) were non-adherent to one or more of their regular medications at follow-up. Intentional and unintentional non-adherence contributed equally.It was noted that the presence of a carer responsible for medications was associated with a significantly lower non-adherence rate. They suggest that the prescribing physicians need to establish a better therapeutic relationship with their patients as this may reduce intentional non-adherence. Internal Medical Journal 2016;46,185-192 Metformin versus placebo in obese pregnant women without diabetes mellitusObesity is associated with an increased risk of adverse pregnancy outcomes. Metformin improves insulin sensitivity and in pregnant patients with gestational diabetes it leads to less weight gain than occurs in those who do not take metformin.This trial aimed to assess whether metformin administered to obese pregnant women from 12-18 weeks of gestation would reduce the median neonatal birth weight as well as the incidences of adverse neonatal outcomes. There were 202 women in the metformin group and 198 in the placebo group.There was no significant difference in the median neonatal birth weights between the metformin and placebo groups. There were also no differences between the groups in the incidence of gestational diabetes, large-for-gestational-age neonates, or adverse neonatal outcomes. N Eng J Med 2016;374:434-43

Summary

Abstract

Aim

Method

Results

Conclusion

Author Information

Acknowledgements

Correspondence

Correspondence Email

Competing Interests

Contact diana@nzma.org.nz
for the PDF of this article

Subscriber Content

The full contents of this pages only available to subscribers.
Login, subscribe or email nzmj@nzma.org.nz to purchase this article.

LOGINSUBSCRIBE